The Role of SGLT2 Inhibitors in Cardiometabolic Protection in the Broader Type to Diabetes Population

There remains a gap on how early to introduce these agents for cardio renal protection in the broader type to diabetes population, particularly if there is no advanced risk or establish atherosclerotic cardiovascular disease. A concerted effort across all relevant sectors is required to ensure that all people have access to such guideline-directed therapy with proven benefits. The full translational cycle of scientific inquiry and evidence generation will be able to affect global cardiometabolic health.